市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Nuvalent, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
| 分析师共识 | -0.5 |
| 内部交易活动 | -3.0 |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.40 |
|
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company’s operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 2.83% |
| 机构持股比例 | 110.08% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Commodore Capital Lp | 31 Mar 2025 | 1,855,000 |
| Boxer Capital, Llc | 30 Sep 2024 | 1,120,192 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| PELISH HENRY E. | - | 78.02 | -200 | -15,604 |
| 累积净数量 | -200 | |||
| 累积净值 ($) | -15,604 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 78.02 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| PELISH HENRY E. | 职员 | 06 Jun 2025 | 自动卖出 (-) | 200 | 78.02 | 15,604 |
| PELISH HENRY E. | 职员 | 06 Jun 2025 | 执行期权 | 200 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合